Advertisement
"These meetings are important opportunities for us to engage in scientificdialogue about the promise of our menstrual blood stem cells, specificallydemonstrating their potential future applicability in a wide area oftherapeutics and medicine," said Julie Allickson, Ph.D., Vice President ofLaboratory Operations and Research and Development at Cryo-Cell.
Advertisement
During the ECAAAM conference, Cryo-Cell will address how early research issuggesting a role for these important stem cells in anti-aging medicine. Themeeting will cover advances in anti-aging and aesthetic medicine technologies,and will highlight innovative new developments in stem cell therapies. TheAABB meeting in October will showcase advances in blood banking, transfusionmedicine and cellular and related biologic therapies. Cryo-Cell's extensiveexperience in cord blood banking and novel MenSC research and development willcontribute to the discussions in advancing transfusion practices and improvingpatient outcomes. Cryo-Cell will also be presenting data related to theproliferative capacity of MenSCs.
Cryo-Cell International continues to build a robust intellectual property(IP) portfolio on MenSCs while expanding its fast-emerging network of globalresearch partnerships. Early studies of the stem cells in menstrual bloodhave confirmed that they have the capability to differentiate rapidly andplentifully into important cells, such as bone, cartilage, fat, nerve andcardiogenic cells. These are non-controversial adult stem cells that are easyto extract and cause no pain to the donor, making them an important andpotentially valuable alternative to other stem cell sources. With additionalstudies, the use of these cells may lead to treatments for a number of seriousdiseases, such as stroke, Alzheimer's and Parkinson's disease. The cells mayeven one day be used for customized anti-aging or sports medicine treatments.
Cryo-Cell's C'elle(SM) service, which was first introduced in November,2007, is the first available product that enables women to collect menstrualflow containing stem cells, which can then be cryogenically preserved in amanner similar to stem cells from umbilical cord blood.
About Cryo-Cell International, Inc. (OTCBB: CCEL.OB)
Based in Oldsmar, Florida, with over 155,000 clients worldwide, Cryo-Cellis one of the largest and most established family cord blood banks. ISO9001:2000 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded company. OTC Bulletin BoardSymbol: CCEL. For more information, please call 1-800-STOR-CELL (1-800-786-7235) or visit www.cryo-cell.com.
Forward-Looking Statement
Statements wherein the terms "believes", "intends", "projects" or"expects" as used are intended to reflect "forward-looking statements" of theCompany. The information contained herein is subject to various risks,uncertainties and other factors that could cause actual results to differmaterially from the results anticipated in such forward-looking statements orparagraphs, many of which are outside the control of the Company. Theseuncertainties and other factors include the uncertainty of market acceptanceof any potential service offerings relating to types of stem cells other thancord blood stem cells, including the C'elle service, given that menstrual stemcells and other new stem cells have not yet been us
